Nursing Elites

1. A client has a new prescription for Furosemide to treat heart failure. Which of the following laboratory results should the nurse monitor?

• A. Potassium level
• B. Sodium level
• C. Hemoglobin A1C
• D. BUN

Correct answer: A

Rationale: The nurse should monitor the client's potassium levels when taking Furosemide because the medication can lead to hypokalemia. Hypokalemia is a potential side effect of Furosemide, a loop diuretic, due to increased potassium excretion in the urine. Monitoring potassium levels is crucial to prevent complications such as cardiac dysrhythmias associated with low potassium levels. Therefore, choices B (Sodium level), C (Hemoglobin A1C), and D (BUN) are incorrect as they are not directly influenced by Furosemide therapy for heart failure.

2. A healthcare provider is reviewing a client's health record and notes that the client experiences permanent extrapyramidal effects caused by a previous medication. The healthcare provider should recognize that the medication affected which of the following systems in the client?

• A. Cardiovascular
• B. Immune
• C. Central nervous
• D. Gastrointestinal

Correct answer: C

Rationale: The correct answer is C: Central nervous. Extrapyramidal effects are movement disorders that can be caused by certain medications affecting the central nervous system, such as typical antipsychotic medications. These effects can lead to symptoms like tremors, muscle rigidity, and involuntary movements, which are all related to disruptions in the central nervous system. Choices A, B, and D are incorrect because extrapyramidal effects are specifically associated with the central nervous system and not the cardiovascular, immune, or gastrointestinal systems.

3. A client has been prescribed Valsartan. Which of the following adverse effects should the nurse monitor?

• A. Hyperkalemia
• B. Hypoglycemia
• C. Bradycardia
• D. Hypercalcemia

Correct answer: A

Rationale: Corrected Rationale: Valsartan is an angiotensin II receptor blocker (ARB) that can lead to hyperkalemia by inhibiting the action of aldosterone. Hyperkalemia is a potential adverse effect, making it essential for the nurse to closely monitor the client's potassium levels to prevent complications such as cardiac arrhythmias. Incorrect Options Rationale: - Option B, Hypoglycemia, is not a common adverse effect of Valsartan. - Option C, Bradycardia, is not typically associated with Valsartan use. - Option D, Hypercalcemia, is not a known adverse effect of Valsartan; instead, Valsartan can lead to hyperkalemia.

4. When teaching a client with a new prescription for nitroglycerin patches, which of the following instructions should the nurse include?

• A. Apply the patch at the same time every day.
• B. Rotate the application site daily.
• C. Remove the patch for 12 hours each day.
• D. Cut the patch in half if needed.

Correct answer: B

Rationale: The correct instruction for a client with a new prescription for nitroglycerin patches is to rotate the application site daily. This is important to prevent skin irritation and ensure optimal absorption of the medication. Applying the patch at the same time every day (Choice A) is not necessary for nitroglycerin patches. Removing the patch for 12 hours each day (Choice C) would disrupt the continuous delivery of medication. Cutting the patch in half (Choice D) can alter the dose and is not recommended unless directed by a healthcare provider.

5. A client is receiving imatinib. Which of the following adverse effects should the nurse monitor?

• A. Edema
• B. Constipation
• C. Dry mouth
• D. Urinary retention

Correct answer: A

Rationale: The correct answer is A: Edema. The nurse should monitor the client for edema when receiving imatinib. Imatinib, a tyrosine kinase inhibitor, can lead to fluid retention and edema as a common adverse effect. This can manifest as swelling in various parts of the body, indicating the need for close monitoring by the nurse to prevent complications related to fluid overload. Choices B, C, and D are incorrect because constipation, dry mouth, and urinary retention are not typically associated with imatinib use. Therefore, they are not the priority adverse effects to monitor in a client receiving this medication.

Similar Questions